From here on in BOD is here for the duration (one year further)...

From here on in BOD is here for the duration (one year further) and remunerations granted, from this you could expect there is a general consensus that there is future upside in the offering.

IF not there will be accountability at next AGM, for what that may be worth.

All will be dependent, imo, on Admedus coming up with further funds that ARE non- dilutive in the immediate future.

@DV, really at a loss why you seem to think WP has no need to be accountable for the company’s present position, right or wrong, coming up to 3 years now, too many of his calls have been for nought. That this is due to ‘murkiness’ etc etc, makes investing in species a sheer ‘pig in the poke’ exercise, this would be belied by WPs own comments of being bankable, super positive tweets etc etc.

Accountability doesn’t mean extreme measures, scrutiny of his actions though is quite warranted, imo.

@suziki, at a loss why Edwardes LS would ditch their own product for ours, Admedus IP would have to be at least 20 % plus superior to their own, ELS product ten years in the making plus how much spent getting to that point. They have mega bucks to upgrade their product, I really believe that Admedus IP will be sought after by a major entity wishing to enter this market.

On the vacc front, yes seemingly dead in the water, but do not discount the sheer volume this vacc has the potential to cater for, this includes the hpv vacc also.

Not expecting much May 21st, content to wait this out for the duration, if the ASIC keen to look after RIs then it shouldn’t be a problem for them to allow Admedus to sort their shite out.